“Market efficiency initiatives and an iEdge Next 50 inclusion should support institutional demand, alongside buybacks and dividends,” says Jaiswal.
RHB Group Research's Shekhar Jaiswal is reiterating his "buy" call on Raffles Medical Group (SGX:BSL
) with an unchanged target price of $1.15.
In his Jan 23 report, Jaiswal states that Raffles Medical offers exposure to a “high-quality Singapore healthcare compounder” with improving earnings visibility.
